Clever Culture Systems (ASX:CC5) said it received a second purchase order from an additional Bristol Myers Squibb facility for its Automated Plate Assessment System Independence technology, which is expected to form a case study for the potential roll out to other Bristol Myers Squibb sites, according to a Wednesday Australian bourse filing.
It said that the sales pipeline for the pharmaceutical industry consisted of over 40 active and qualified customer opportunities, representing an estimated AU$75 million in potential upfront sales revenue and AU$15 million per annum in recurring revenue.
A multinational pharmaceutical firm is evaluating its technology, which automates the imaging, analysis, and interpretation of microbiology culture plates, covering over 6,000 plates, with the resulting data currently being compiled. The evaluation assessed the performance of the settle plate analysis module and is being extended to the contact plate analysis module.
Its shares jumped 6% on market close on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。